Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 257Lymphoid 233Myeloid 139Plasma cell 119Sarcoma 56Classical hematology 54CNS 52Dermatologic 48Breast 45Genitourinary 35Gynecologic 29Other neoplasm 9Other solid neoplasm 7Thoracic 5Head & Neck 4Gastrointestinal 4Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Peripheral Blood Stem Cell Transplantation × Tumor-Agnostic × Clear all
NCT01525407 2017-08-17

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

Fred Hutchinson Cancer Center

Phase 2 Completed
83 enrolled 16 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡